TRIM59 DIRECTED DIAGNOSTICS FOR NEOPLASTIC DISEASE
First Claim
Patent Images
1. A method for detecting a neoplasm comprising:
- a) obtaining a potentially neoplastic test sample and a corresponding non-neoplastic control sample;
b) detecting a level of TRIM59 expression in the test sample and in the control sample; and
c) comparing the level of TRIM59 expression in the test sample to the level of TRIM59 expression in the control sample,the test sample being neoplastic if the level of TRIM59 expression in the test sample is detectably greater than the level of TRIM59 expression in the control sample.
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed are methods for diagnosing cancer in a test cell sample or fluid sample by detecting an increase in the level of expression of TRIM59 in the test cell sample or fluid sample as compared to the level of expression of TRIM59 in a control cell sample or fluid sample isolated from a normal subject.
43 Citations
33 Claims
-
1. A method for detecting a neoplasm comprising:
-
a) obtaining a potentially neoplastic test sample and a corresponding non-neoplastic control sample; b) detecting a level of TRIM59 expression in the test sample and in the control sample; and c) comparing the level of TRIM59 expression in the test sample to the level of TRIM59 expression in the control sample, the test sample being neoplastic if the level of TRIM59 expression in the test sample is detectably greater than the level of TRIM59 expression in the control sample. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)
-
-
20. A method for detecting a neoplasm comprising:
-
a) obtaining a potentially neoplastic test sample and a non-neoplastic control sample; b) detecting a level of TRIM59 expression in the test sample and in the control sample; c) detecting a level of expression of at least one of TTK, SLC7A5, UHRF1, and/or KIF20A; and d) comparing the level of TRIM59 expression and the level of expression of at least one of SLC7A5, UHRF1, TTK, and/or KIF20A in the test sample to the level of TRIM59 expression and the level of expression of the at least one of SLC7A5, UHRF1, TTK, and/or KIF20A in the control sample, the test sample being neoplastic if the levels of expression of TRIM59 and the at least one of SLC7A5, UHRF1, TTK, and/or KIF20 in the test sample are detectably greater than the levels of expression of TRIM59 and the at least one of SLC7A5, UHRF1, TTK, and/or KIF20A in the control sample. - View Dependent Claims (21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)
-
-
33. A kit for diagnosing or detecting neoplasia, comprising:
-
a) a first probe specific for the detection of TRIM59; and b) a second probe specific for the detection of a neoplasia marker selected from the group consisting of SLC7A5, UHRF1, TTK, KIF20A, and combinations thereof.
-
Specification